VCEL logo

VERICEL CORP

VCELNASDAQ
πŸ† #1809 by market capEarnings Feb 25US Equity
$57.52β–Ό $0.74 (βˆ’1.27%)
Market closed Β· at close
πŸ””
Track VCEL
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 1.3%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$2.95B
Small Cap
πŸ“ˆRevenue Growth (YoY)
25.3%
High Growth
πŸ“ŠGross Margin
74.5%
High
πŸ’΅FCF Margin
17.9%
Healthy
βš–οΈP/S Ratio
9.2x
Elevated
Otter Score
88
Excellent
No chart data available for VCEL.

Trading Snapshot

Day Range
$57.39 – $59.49
52-Week Range
$28.95 – $59.75
Volume (shares)
582,337
Avg Volume (shares)
β€”
Shares Outstanding
51.2M
Next Earnings
2027-02-25

Fundamentals Snapshot

Annual Revenue
$276M
Last Q Revenue
$85M
P/E Ratio
89.2
P/S Ratio
9.2x
EPS (TTM)
$0.59
Dividend Yield
β€”
Dilution (1yr)
βˆ’0.3%
VCEL logo

VERICEL CORP

VCEL
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$276Mβ–² +16.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
74.4%β–² +2.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$11Mβ–² +144.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$25Mβ–Ό βˆ’525.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
52.1Mβ–Ό βˆ’0.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$2Mβ–² +$26M YoY
StockOtter Β· stockotter.space

About VERICEL CORP

Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Excellent
88/100
Analyst data unavailable.

Latest News & Updates

News unavailable.